Many of you probably consider, not having met me, that I am a nerdish multiple sclerosis neurologist, uninterested in anything outside of this disease. Just to show you what a cultivated, renaissance man I am, I came across this paragraph when reading from Tom Holland's new translation of "The Histories" by Herodotus (a splendid, accessible, humane and often quite funny, book). 1 The fifth century BC Greek historian Herodotus describes an after-thebattle scene:
The site is strewn with the bones of men from both sides who fell in the battle, with those of the Persians quite distinct from those of the Egyptians, just as they were when the fighting originally began; and so brittle are the skulls of the Persians that, should you wish to make a hole in one, you would have only to tap it with a single pebble, whereas those of the Egyptians are so tough that it would be a challenge to smash them through, even if you pounded at them with a rock. Why should this be so? The locals gave a reason which seems to me eminently plausible: namely, that Egyptians are in the habit of shaving their heads from the very earliest days of their childhood, so that the bone ends up thickened by exposure to the sun. This explanation of the toughness of Egyptian skulls also serves to suggest why Persian skulls should be so brittle: the Persians keep their heads out of the sun from birth by wearing conical felt caps, or tiaras.
Clearly the first-ever observational report of the effects of sunlight, and thus vitamin D intake, in relation to bone structure and human mortality.
Neil Scolding is of course being provocative, one of his many positive attributes (not that he has any negative ones). He is quite right to point out that it has become fashionable to prescribe vitamin D medication in multiple sclerosis without any solid proof that it has any effect whatsoever in this disease. The fault is with us. It is quite remarkable that we have not translated all the epidemiological observations into evidence from a clinical trial. 2, 3 It is hoped that within the next 3−4 years we will have results from the PREVANZ trial in Australia/New Zealand and also the French D-LAY study; there will of course also hopefully be positive evidence from SOLAR and EVIDIMS (both trials using disease-modifying therapies plus vitamin D). 4, 5 Further studies are needed; Neil Scolding mentions the small negative Australian study; however the patients in that study had highly active disease and were unlikely to respond to the dose of vitamin D2 used. 6 I think we all need to accept the admonition; what Neil Scolding is correctly saying is that we really have not moved on from observational studies dating from the fifth century BC. I belong to the school of thought that vitamin D will eventually be shown to have significant therapeutic effects, particularly in combination with other disease-modifying therapies, in relapsing remitting multiple sclerosis.
Definitely the best clinical paper in 2014
Without any doubt, the best clinical research paper of 2014 was the one published by Jeremy Chataway and colleagues in the Lancet on the utility of highdose simvastatin in secondary progressive multiple sclerosis. 7 This landmark paper demonstrated, reasonably unequivocally, evidence of neuroprotection provided by high-dose simvastatin in this otherwise intractable disorder. Clearly further proof is needed; however, in Chataway's paper the effects on cerebral atrophy, by MRI metrics, and disability, measured by the expanded disability severity scale and the multiple sclerosis impact score-29, were truly remarkable. Hopefully with funding, which will need to come from non-industry sources, these results will be reproduced in a phase 3 randomized controlled trial.
